Search clinical trials for: Plerixafor G-CSF

Total 3477 results

Peking University

Recruiting

Plerixafor for Poorly Mobilized Lymphoma

Lymphoma

China
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Hodgkin's Disease

United States
Sanofi

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Combination With G-CSF in Multiple Myeloma Patients

Autologous Haematopoietic Stem Cell Transplant

China
Stephen Couban
Genzyme, a Sanofi Company

Completed

Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor

Malignant Lymphoma, Stem Cell Type

Canada
Genzyme, a Sanofi Company

Approved for marketing

Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization (CUP)

Autologous Stem Cell Transplant
University of Liverpool
Genzyme, a Sanofi Company

Unknown

Plerixafor Harvesting And No Chemotherapy for Transplantation of Autologous STem Cells In Cancer (PHANTASTIC) (PHANTASTIC)

Lymphoma | Lymphoproliferative Disorders | Multiple Myeloma | Plasma Cell Dyscrasia

United Kingdom
Genzyme, a Sanofi Company

Completed

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

Germany
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

Lymphoma, Non-Hodgkin | Multiple Myeloma

Canada
University of Florida

Completed

Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation

Multiple Myeloma | Non-Hodgkin's Lymphoma

United States
Genzyme, a Sanofi Company

Terminated

AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone

Multiple Myeloma | Lymphoma, Non-Hodgkin's

United States
Duke University
Genzyme, a Sanofi Company

Completed

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

Multiple Myeloma | Non-Hodgkins Lymphoma | Hodgkins Disease

United States
Genzyme, a Sanofi Company
AnorMED

Completed

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
Genzyme, a Sanofi Company

Completed

AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts

Autologous Stem Cell Transplantation

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers

Healthy

United States
Assistance Publique - Hôpitaux de Paris
EuroFancolen

Completed

Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor (FancoMob)

Fanconi Anemia

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide

Refractory Multiple Myeloma

United States
Federal Research Institute of Pediatric Hematology...

Unknown

A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients

Hematopoietic Stem Cell Transplantation | Wiskott-Aldrich Syndrome | Graft Failure

Russian Federation
Genzyme, a Sanofi Company

Completed

Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).

Lymphoma | Multiple Myeloma | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
Washington University School of Medicine

Completed

Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant

Stem Cell Transplant Patients

United States
Genzyme, a Sanofi Company

Completed

Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms

Non-Hodgkin's Lymphoma

Korea, Republic of, Taiwan, United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Infections | Warts | Neutropenia | Myelokathexis | Hypogammaglobulinemia

United States
University Hospital Inselspital, Berne

Completed

PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma (PAV)

Myeloma

Switzerland
Genzyme, a Sanofi Company

Completed

Long-Term Follow-up Study for Multiple Myeloma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3102 Study (NCT00103662).

Multiple Myeloma | Autologous Transplantation
French Innovative Leukemia Organisation
Genzyme, a Sanofi Company; Acute Leukemia French Association

Terminated

Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia (PRIMAL)

Acute Myeloid Leukemia

France
M.D. Anderson Cancer Center
Proteonomix, Inc.

Completed

Plerixafor for Stem Cell Mobilization in Normal Donors

Blood And Marrow Transplantation

United States
Zhongnan Hospital

Not yet recruiting

The Value of Peripheral Blood CD34+ Cell Dynamics Monitoring in Autologous Hematopoietic Stem Cell Transplant Mobilization

Granulocyte Colony-Stimulating Factor

China
Stanford University

Recruiting

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging

Cervix Cancer | Endometrial Cancer

United States
Sun Yat-sen University

Recruiting

PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure

PD-1 Inhibitor | G-CSF

China
Institute of Liver and Biliary Sciences, India

Completed

Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis

Severe Alcoholic Hepatitis

India
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia

Diamond Blackfan Anemia

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Mobilization Potential in Patients With Aplastic Anemia in Remission

Aplastic Anemia

United States
Ain Shams University

Completed

Enteral Granulocyte Colony Stimulating Factor and Erythropoietin Early in Life Increases Feeding Tolerance in Preterm Infants: A Randomized Controlled Trial

Necrotizing Enterocolitis | Feeding Intolerance
Washington University School of Medicine

Completed

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Axaron Bioscience AG

Completed

Treatment With AX200 for Acute Ischemic Stroke

Cerebral Stroke

Germany
Washington University School of Medicine

Completed

Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin | Multiple Myeloma

United States
University Hospital Inselspital, Berne

Completed

Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

Coronary Artery Disease

Switzerland
Proteonomix, Inc.
University of Medicine and Dentistry of New Jersey; Numoda

Unknown

Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease

End Stage Liver DIsease

United States
Gurgan Clinic

Completed

Intrauterine G-CSF Administration in RIF (G-CSF)

Infertility

Turkey
Genzyme, a Sanofi Company

Completed

Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).

Non-Hodgkin's Lymphoma | Autologous Transplantation
Hospital Universitario Dr. Jose E. Gonzalez

Unknown

Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation

Lymphoma, Non-Hodgkin | Myeloma | Lymphoma, Hodgkin | Stem Cell Transplant Complications

Mexico
Centre for Endocrinology and Reproductive Medicine...

Unknown

Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF

Infertility | Embryo Development | IVF

Italy
Mayo Clinic

Completed

Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

Multiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple Myeloma

United States
National Heart, Lung, and Blood Institute (NHLBI)
New York University and New York Genome Center

Recruiting

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Graft-Versus-Host Disease | Graft-versus-leukemia | Donor Apheresis

United States
GPCR Therapeutics, Inc.

Completed

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

United States
Xinhua Hospital, Shanghai Jiao Tong University...

Unknown

G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor

Lymphoma | Acute Myeloid Leukemia | Neuroblastoma | Retinoblastoma | Hepatoblastoma | Acute Lymphoid Leukemia

China
National Institute of Allergy and Infectious Diseases...

Completed

G-CSF to Treat Crohn's Disease

Crohn's Disease

United States
Genzyme, a Sanofi Company

Completed

The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)

Hodgkin Disease | Non-Hodgkin Lymphoma

United States
Siddhartha Ganguly

Completed

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Multiple Myeloma

United States
Seoul St. Mary's Hospital

Unknown

Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML (DeGREE)

Leukemia, Myeloid, Acute

Korea, Republic of

3

Subscribe